At the annual general meeting of shareholders of Siegfried Holding AG (SIX: SFZN) of April
14, 2010 all motions submitted by the Board of Directors were approved, in particular the
creation of limited capital as the basis for issuing mandatory convertible notes of up to 80
million Swiss francs. Furthermore, the restrictions on transferability of the company’s registered
shares were deleted.
Siegfried’s Honorary Chairman, Bernard A. Siegfried, retired from the Board of Directors after
serving the company for 40 years and was bid farewell. Andreas Casutt, a Zurich based
commercial lawyer, was appointed to the Board. Malcolm Perkins, the representative of Camellia
Plc. of the United Kingdom, declared his retirement from the Board effective April 15,
2010. The execution of the sale of a large part of the Siegfried stock owned by Camellia Plc.
is scheduled for that day.
In his speech to Siegfried’s shareholders, Chairman Markus Altwegg stated that the current
fiscal year had begun on a positive note: “In the first quarter we reported sales of 57.3 million
Swiss francs representing a growth of 4.1 percent above prior year, and operating results are
also developing positively”.
About Siegfried
Active in Life Science markets, the Siegfried Group is a global manufacturer of pharmaceutical products with
production facilities located in Switzerland, Germany, Malta and the USA, Siegfried currently has approximately
850 employees and achieved annual sales of approx. CHF 283 million in 2009.
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures
active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding
intermediate steps and standard products, and provides development and production services for drugs
in finished dosage forms.
Siegfried Holding AG is listed on the Swiss Exchange in Zurich (SWX: SFZN).
